title: Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?
abstract: BACKGROUND
  Endoscopic ultrasound (EUS) is considered the best technique for locoregional staging at diagnosis but its role in the follow-up of patients with gastric lymphoma after organ-conserving strategies has not been established.
  
  
  METHODS
  We retrospectively evaluated 23 patients with primary gastric lymphoma treated with a stomach-conservative approach. Sixteen of them were affected by MALT lymphoma and seven by diffuse large-B-cell lymphoma (DLBCL). Five patients were treated with Helicobacter pylori (HP) eradication therapy alone (omeprazole + amoxicillin + clarithromycin); eight patients received a treatment including HP eradication and chemotherapy and the remaining 10 patients were treated with chemotherapy alone.
  
  
  RESULTS
  At the end of treatment, a complete remission was documented in 21 (91%) patients by endoscopy with biopsy (E-Bx) but in only seven (30%) patients by EUS. A total of 99 evaluations with both EUS and E-Bx were evaluated and we found concordance between the two methods in 33 occasions (33%) only. No significant difference on the percentage of concordance was recorded between MALT and DLBCL. After a median follow-up of 36.5 months we have not observed any relapse in 12 patients (six DLBCL and six MALT) with a persistent positive EUS but negative E-Bx.
  
  
  CONCLUSIONS
  Although the length of follow-up cannot exclude late relapse, we think that in restaging and follow-up of gastric lymphoma, EUS seems not to be a reliable tool if it is abnormal and E-Bx still remains the gold standard. Therefore, after conventional conservative treatment, persistence of EUS abnormality with a negative histology should not be considered as a clinically relevant persistence of disease and should not be a reason for further treatment.
authors.affiliation: Divisione Clinicizzata di Ematologia, Università di Catania, Ospedale Ferrarotto, Catania, Italy. diraimon@unict.it
authors.forename: F
authors.initials: F
authors.lastname: Di Raimondo
authors.forename: L
authors.initials: L
authors.lastname: Caruso
authors.forename: G
authors.initials: G
authors.lastname: Bonanno
authors.forename: P
authors.initials: P
authors.lastname: Naso
authors.forename: A
authors.initials: A
authors.lastname: Chiarenza
authors.forename: P
authors.initials: P
authors.lastname: Fiumara
authors.forename: A
authors.initials: A
authors.lastname: Bari
authors.forename: G A
authors.initials: GA
authors.lastname: Palumbo
authors.forename: A
authors.initials: A
authors.lastname: Russo
authors.forename: R
authors.initials: R
authors.lastname: Giustolisi
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019160:Endosonography; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents